Communiqués Arcutis Biotherapeutics, Inc.

Actions

ARQT

US03969K1088

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 16:39:17 10/08/2026			Varia. 5j.	Varia. 1 janv.
25,60 ^USD	+1,21%		-1,79%	-12,28%

06/08	Transcript : Arcutis Biotherapeutics, Inc., Q2 2026 Earnings Call, Aug 05, 2026
05/08	Arcutis Biotherapeutics, Inc. annonce des changements au sein de sa direction	CI

Communiqués

07/08	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/08	Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update	GL
16/07	Arcutis Expands Board of Directors with Appointment of Chris Peetz	GL
16/07	Arcutis Expands Board of Directors with Appointment of Chris Peetz	AQ
15/07	Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026	AQ
09/07	FDA Accepts Supplemental New Drug Application for Arcutis ZORYVE Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months	AQ
08/07	Arcutis Biotherapeutics : FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the	PU
08/07	FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months	GL
02/07	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/07	Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE Indications	AQ
30/06	Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications	GL
30/06	Arcutis Biotherapeutics : FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Chil	PU
30/06	FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2	GL
05/06	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/06	Arcutis Biotherapeutics - New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology	AQ
03/06	New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology	GL
03/06	New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology	AQ
26/05	Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference	AQ
08/05	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
07/05	Arcutis Biotherapeutics : Presentation Q1 2026 Financial Results	PU
06/05	Arcutis Biotherapeutics : Press Release Q1 2026 Financial Results	PU
06/05	Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update	GL
27/04	Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months	GL
27/04	Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months	AQ
22/04	Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines	GL